Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -1M | -1M | 0 | 0 |
| Operating Income | -143M | -143M | -111M | -92M | -79M |
| EBITDA | -128M | -127M | -110M | -86M | -78M |
| Net Income | -129M | -128M | -101M | -89M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$9.45
+0.16% today
1Y Change
-15.14%
Window
Jun 26, 2025 → Jun 23, 2026
Coverage: 248 bars · Jun 26, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ORIC Pharmaceuticals, Inc. (ORIC) is a Healthcare stock with a market cap of $980.00M and listed on NASDAQ. The stock last traded around $9.45 and down 15.1% across the available one-year price window (Jun 26, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +19.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +19.7%, free cash flow -0.2% with operating margin 0.0% and ROIC -36.3%. Stock Foundry combines ORIC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORIC
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORIC Max Drawdown
-48.13%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ORIC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$78.7M
+11.7% YoY
Free Cash Flow
-$60.5M
+21.7% YoY
Revenue Growth
+0.0%
EPS Growth
+19.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | -1M | -1M | 0 | 0 |
| Operating Income | -143M | -143M | -111M | -92M | -79M |
| EBITDA | -128M | -127M | -110M | -86M | -78M |
| Net Income | -129M | -128M | -101M | -89M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 46M | 59M | 23M | 67M | 226M |
| Total Assets | 411M | 274M | 255M | 250M | 299M |
| Total Liabilities | 27M | 31M | 31M | 28M | 26M |
| Shareholder Equity | 384M | 243M | 224M | 222M | 273M |
| Total Debt | 12M | 3M | 10M | 12M | 2M |
| Net Debt | -34M | -56M | -13M | -55M | -224M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
+20.8% YoY
Capital Expenditures
939K
+54.8% YoY
Free Cash Flow
60M
+21.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.8%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.